Biocon Biologics, India’s pride in global biotech, has just scored a major win. The US Food and Drug Administration (USFDA) has approved Kirsty, a fast-acting insulin used to treat diabetes. Kirsty is a biosimilar of Novolog and is now the first and only interchangeable biosimilar rapid-acting Insulin Aspart approved in the U.S.
This is a huge deal. It means that Kirsty can now be swapped with Novolog at pharmacies without needing a new prescription. That’s big for patients and bigger for Biocon Biologics.
What is Kirsty?
Kirsty is used to help control blood sugar in both adults and children who have diabetes. It works fast. It can be taken through a prefilled pen for under-the-skin use, or from a vial for both subcutaneous and intravenous use.
This approval adds to Biocon Biologics’ growing insulin lineup. The company had already made waves with Semglee, the first approved interchangeable biosimilar for long-acting insulin (Insulin Glargine).
Now with Kirsty, they’ve doubled down.
Why This Matters
Let’s look at the numbers. The U.S. has 38.4 million people living with diabetes. Nearly one in four don’t even know they have it. And almost 98 million more are prediabetic.
In 2024 alone, sales of Insulin Aspart in the U.S. touched $1.9 billion. It’s a massive market — and Kirsty is stepping right into it with affordability and access.
Kirsty was already approved in Europe and Canada since 2022. But this U.S. approval? It’s the crown jewel.
What Biocon Biologics Says
Shreehas Tambe, CEO of Biocon Biologics, called this a proud moment.
“With Kirsty, we are expanding treatment choices for people with diabetes,” he said. “We want to make insulin more affordable and accessible. This builds on what we started with Semglee.”
It’s not just about business. It’s about impact.
Biocon Biologics is part of Biocon, a leading Indian biopharma company focused on chronic diseases like diabetes, cancer, and autoimmune conditions. Their goal is clear — make high-quality drugs affordable for more people.
Also Read Glenmark Pharma Receives USFDA Warning for Indore Facility, Says Supply Unaffected
